This document is a patent publication from the European Patent Office (EPO) for a binding molecule, identified as EP4630448A1, filed by Strike Pharma AB. The publication date is March 18, 2026. It details International Patent Classifications (IPC) such as C07K 16/12, C07K 16/28, A61K 39/12, A61K 39/39, C07K 14/33, and A61P 35/00, indicating its relevance to antibody technology, pharmaceutical compositions, and therapeutic uses, particularly in treating cancer.

This publication represents the grant of a patent or the publication of a pending application, providing intellectual property protection for the applicant. For compliance officers in the pharmaceutical sector, this indicates a new patent in the field of binding molecules, potentially impacting research and development strategies, licensing opportunities, and competitive landscapes. No immediate compliance actions are required based solely on this publication, but it signals ongoing innovation and potential future market exclusivity for Strike Pharma AB's technology.